Profile data is unavailable for this security.
About the company
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
- Revenue in NOK (TTM)68.05m
- Net income in NOK-419.70m
- Incorporated2007
- Employees179.00
- LocationNykode Therapeutics ASAOslo Science Park, Gaustadalleen 21OSLO 0349NorwayNOR
- Phone+47 22958193
- Fax+47 22604427
- Websitehttps://nykode.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promimic AB | 40.96m | -10.46m | 534.13m | 17.00 | -- | 7.52 | -- | 13.04 | -0.563 | -0.563 | 2.21 | 3.80 | 0.4828 | -3.88 | 3.92 | 2,406,824.00 | -12.33 | -24.89 | -14.16 | -29.25 | 104.60 | 101.23 | -25.54 | -89.47 | 4.51 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Arcticzymes Technologies ASA | 108.19m | 7.00m | 669.04m | 68.00 | 95.84 | 2.10 | 51.51 | 6.18 | 0.1367 | 0.1367 | 2.10 | 6.24 | 0.3199 | 0.45 | 1.93 | 1,591,059.00 | 2.07 | 15.58 | 2.19 | 17.22 | 93.99 | 96.69 | 6.47 | 33.23 | 14.95 | -- | 0.0273 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| Thor Medical ASA | 0.00 | -18.56m | 689.31m | 1.00 | -- | 2.65 | -- | -- | -0.0873 | 0.021 | 0.00 | 1.11 | 0.00 | -- | -- | 0.00 | -9.82 | -79.17 | -10.54 | -113.94 | -- | -- | -- | -- | -- | -- | 0.0035 | -- | -- | -- | -- | -- | -- | -- |
| Nykode Therapeutics ASA | 68.05m | -419.70m | 906.75m | 179.00 | -- | 0.5386 | -- | 13.33 | -1.35 | -1.35 | 0.2128 | 5.16 | 0.0333 | -- | 1.59 | 393,326.30 | -20.57 | 5.65 | -23.15 | 6.38 | -- | -- | -616.79 | 18.13 | -- | -- | 0.0305 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Intellego Technologies AB | 231.48m | 82.95m | 1.05bn | 62.00 | 12.15 | 4.49 | 11.56 | 4.53 | 3.03 | 3.03 | 8.50 | 8.20 | 0.8298 | 4.24 | 2.45 | 3,729,807.00 | 29.74 | -- | 37.90 | -- | 68.61 | -- | 35.83 | -- | 1.88 | 8.84 | 0.1532 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -258.31m | 1.28bn | 24.00 | -- | 2.42 | -- | -- | -7.81 | -7.81 | 0.00 | 17.14 | 0.00 | -- | -- | 0.00 | -37.64 | -18.38 | -40.48 | -19.26 | -- | -- | -- | -- | 1.51 | -- | 0.0543 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Diamyd Medical AB | 131.13k | -152.00m | 1.29bn | 28.00 | -- | 8.68 | -- | 9,801.27 | -1.60 | -1.60 | 0.0014 | 1.46 | 0.0006 | -- | 3.20 | 4,678.57 | -71.82 | -34.32 | -83.67 | -38.45 | -10,083.21 | -3,111.20 | -115,916.00 | -17,499.13 | -- | -- | 0.1737 | -- | -76.19 | -39.23 | -30.82 | -- | -- | -- |
| Nightingale Health Oyj | 50.54m | -202.52m | 1.32bn | 86.00 | -- | 2.05 | -- | 26.07 | -0.2895 | -0.2895 | 0.0722 | 1.37 | 0.0441 | 2.33 | 3.46 | 50,674.42 | -17.67 | -14.59 | -18.99 | -15.99 | 66.45 | 77.90 | -400.71 | -435.73 | 9.74 | -- | 0.0308 | -- | 4.21 | 16.13 | 3.43 | -- | 8.54 | -- |
| Nanoform Finland Oyj | 26.61m | -251.27m | 1.34bn | 174.00 | -- | 1.63 | -- | 50.40 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
Data as of Nov 22 2024. Currency figures normalised to Nykode Therapeutics ASA's reporting currency: Norwegian Krone NOK
14.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 15.05m | 4.61% |
| Vatne Capital ASas of 31 Dec 2023 | 7.38m | 2.26% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 5.46m | 1.67% |
| DNB Asset Management ASas of 30 Sep 2024 | 5.07m | 1.55% |
| Danske Invest Asset Management ASas of 31 Oct 2024 | 4.09m | 1.25% |
| First Fondene ASas of 30 Jun 2024 | 3.50m | 1.07% |
| Schroder Investment Management Ltd.as of 31 Jul 2024 | 2.23m | 0.68% |
| Storebrand Asset Management ASas of 30 Sep 2024 | 1.93m | 0.59% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 1.17m | 0.36% |
| Pareto Asset Management ASas of 30 Jun 2024 | 644.13k | 0.20% |
More ▼
Data from 30 Apr 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
